Brings down the risk of coronary heart disease by 62% and Stroke by 48%*
*“The Indian Polycap Study”, published in “The Lancet”
Breakthrough in the management of squamous NSCLC
A boosted-Rifampicin containing fixed-dose combination, anti-tubercular drug
Rabeprazole in I.V. form
A unique immuno-modulator reducing duration of therapy for treatment of multi drug resistant tuberculosis and multibacillary leprosy
A naked eye rapid HIV detection kit
At Cadila Pharmaceuticals, there is a sharp focus on Research and Development. Naturally, Innovation is at the centre of all of activities. A slew of innovative products down the years bear testimony to this.In 2009, Cadila Pharmaceuticals emerged on the world map with the development of Polycap – a novel drug and world’s first drug combination for prevention of Cardiovascular Diseases. Click here to view Polycap video
The company believes in forging Public-Private partnerships for developing diagnostic, preventive and curative pharmaceutical and diagnostic products. Many innovations have resulted from such partnerships. Among them is ‘Immuvac’- a unique immuno-modulator that has various applications including reduction in duration of therapy for treatment of multi drug resistant tuberculosis and multibacillary leprosy.
‘NEVA’ – a rapid HIV detection kit and Risorine – the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis are two other innovations which have received much acclaim. Click here to view Risorine video
Recently, Cadila Pharmaceuticals offered to the world, Mycidac-C, the first in the world innovative and affordable product for the patients suffering from Non Small Cell Lung Cancer (NSCLC), one of the main types of Lung Cancers. Click here to view Mycidac-C video.
The company was also the first in the world to introduce Rabeprazole in IV form.
With Biotech, Vaccine adjuvants, Stem cells banking as few other thrust areas, Cadila Pharmaceuticals now covers the entire spectrum of human healthcare. In fact, the company has chalked out robust plan to add one/two biotech products every year.
Cadila Pharmaceuticals has the highest number of commercialized biological products to its credit as compared to any other pharmaceuticals company in the state of Gujarat, India.